Moderna D
D
MRNA
246.890
USD
-3.92
(-1.56%)
Pre Open·252.480USD+5.590(+2.26%)
Last updated: · Delayed 15 min
Moderna price to sales (P/S) ratioWhat is the P/S ratio? The price-to-sales ratio compares a company's market value with its revenue over the last year: what you pay for each dollar of sales.
Moderna's P/S ratio is 39.56: its market cap of 99.90B USD over revenue of 2.53B USD in the last twelve months.
- Today
- 39.56
- Average, 5 years
- 6.32
- Low, 5 years
- 2.10
- High, 5 years
- 45.90
P/S ratio = market cap ÷ revenue (last 12 months) = 99.90B ÷ 2.53B = 39.56
Each day's market cap over the revenue of the last four quarters reported by that day.
P/S ratio by year and by quarter
| Fiscal year | Period ending | P/S ratio | Market cap | Revenue |
|---|---|---|---|---|
| Today | 39.56 | 99.90B | 2.53B | |
| FY2025 | 31 Dec 2025 | 5.90 | 11.47B | 1.94B |
| FY2024 | 31 Dec 2024 | 4.99 | 15.97B | 3.20B |
| FY2023 | 31 Dec 2023 | 5.55 | 37.99B | 6.85B |
| FY2022 | 31 Dec 2022 | 3.75 | 70.77B | 18.88B |
| FY2021 | 31 Dec 2021 | 5.77 | 102.35B | 17.74B |
| FY2020 | 31 Dec 2020 | 49.59 | 39.84B | 803.40M |
| FY2019 | 31 Dec 2019 | 107.47 | 6.47B | 60.21M |
| FY2018 | 31 Dec 2018 | 37.17 | 5.02B | 135.07M |
| FY2017 | 31 Dec 2017 | 33.98 | 6.99B | 205.83M |
| FY2016 | 31 Dec 2016 | 11.00 | 1.19B | 108.40M |
| Quarter | Period ending | P/S ratio | Market cap | Revenue |
|---|---|---|---|---|
| Q3 FY2026 | 30 Sept 2026 | 30.58 | 77.22B | 2.53B |
| Q2 FY2026 | 30 Jun 2026 | 12.45 | 27.73B | 2.23B |
| Q1 FY2026 | 31 Mar 2026 | 9.02 | 20.07B | 2.23B |
| Q4 FY2025 | 31 Dec 2025 | 5.95 | 11.56B | 1.94B |
| Q3 FY2025 | 30 Sept 2025 | 4.54 | 10.07B | 2.22B |
| Q2 FY2025 | 30 Jun 2025 | 3.50 | 10.70B | 3.06B |
| Q1 FY2025 | 31 Mar 2025 | 3.49 | 10.94B | 3.14B |
| Q4 FY2024 | 31 Dec 2024 | 5.00 | 16.01B | 3.20B |
| Q3 FY2024 | 30 Sept 2024 | 5.09 | 25.73B | 5.06B |
| Q2 FY2024 | 30 Jun 2024 | 8.85 | 44.52B | 5.03B |
| Q1 FY2024 | 31 Mar 2024 | 7.83 | 40.34B | 5.16B |
| Q4 FY2023 | 31 Dec 2023 | 5.55 | 37.89B | 6.83B |
| Q3 FY2023 | 30 Sept 2023 | 4.30 | 39.35B | 9.16B |
| Q2 FY2023 | 30 Jun 2023 | 4.39 | 46.29B | 10.55B |
| Q1 FY2023 | 31 Mar 2023 | 4.01 | 59.28B | 14.77B |
| Q4 FY2022 | 31 Dec 2022 | 3.66 | 69.15B | 18.88B |
| Q3 FY2022 | 30 Sept 2022 | 2.23 | 46.12B | 20.68B |
| Q2 FY2022 | 30 Jun 2022 | 2.54 | 56.57B | 22.28B |
| Q1 FY2022 | 31 Mar 2022 | 3.16 | 69.25B | 21.93B |
| Q4 FY2021 | 31 Dec 2021 | 5.80 | 102.86B | 17.74B |
| Q3 FY2021 | 30 Sept 2021 | 13.69 | 155.48B | 11.36B |
| Q2 FY2021 | 30 Jun 2021 | 14.13 | 94.46B | 6.69B |
| Q1 FY2021 | 31 Mar 2021 | 20.64 | 52.38B | 2.54B |
| Q4 FY2020 | 31 Dec 2020 | 51.49 | 41.37B | 803.40M |
| Q3 FY2020 | 30 Sept 2020 | 113.25 | 27.94B | 246.71M |
| Q2 FY2020 | 30 Jun 2020 | 228.97 | 24.23B | 105.84M |
| Q1 FY2020 | 31 Mar 2020 | 201.10 | 10.57B | 52.57M |
| Q4 FY2019 | 31 Dec 2019 | 108.63 | 6.54B | 60.21M |
| Q3 FY2019 | 30 Sept 2019 | 64.55 | 5.27B | 81.57M |
| Q2 FY2019 | 30 Jun 2019 | 45.62 | 4.85B | 106.29M |
| Q1 FY2019 | 31 Mar 2019 | 55.47 | 6.77B | 122.05M |
| Q4 FY2018 | 31 Dec 2018 | 37.17 | 5.02B | 135.07M |
| Q3 FY2018 | 30 Sept 2018 | 31.50 | 6.03B | 191.55M |
| Q2 FY2018 | 30 Jun 2018 | 38.21 | 7.35B | 192.27M |
| Q1 FY2018 | 31 Mar 2018 | 36.89 | 7.35B | 199.14M |
| Q4 FY2017 | 31 Dec 2017 | 26.81 | 5.52B | 205.83M |
| Q3 FY2017 | 30 Sept 2017 | — | 1.20B | — |
| Q2 FY2017 | 30 Jun 2017 | — | 1.19B | — |
| Q1 FY2017 | 31 Mar 2017 | — | 1.19B | — |
Figures in USD. A quarter's revenue, net income and dividends are those of its last four quarters.
See also:Market cap,ROE (return on equity),Debt to equity,Current ratio,All ratios
Common questions about Moderna's P/S ratio
Source: Financial Modeling Prep